TARA - Protara Therapuetics

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Protara Therapeutics files for $300M mixed shelf
• Protara Therapeutics reports Q3 results
• Protara Therapeutics GAAP EPS of -$1.00
• Protara Therapeutics GAAP EPS of -$0.80
• Protara stock surges ~10% on FDA clearance to start trial of rare disease drug
• Protara Therapeutics' TARA-002 shows positive results in phase 1a trial for bladder cancer, stock surges by 8%
• Protara Therapeutics GAAP EPS of -$3.46
• Protara Therapeutics names new CFO
• Selecta Biosciences appoints Protara Therapeutics's Blaine Davis as new CFO
• ArTara Therapeutics GAAP EPS of -$0.68 beats by $0.08
• Protara Therapeutics announces departure of CFO
• ArTara Therapeutics GAAP EPS of -$0.96 misses by $0.06
• Protara begins dosing in early-stage trial of TARA-002 for bladder cancer
• ArTara Therapeutics GAAP EPS of -$0.91 beats by $0.03
• Protara shares surge 17% on FDA greenlight for early-stage TARA-002 bladder cancer trial
• ArTara Therapeutics EPS misses by $0.09
• Protara trades higher as H.C. Wainwright highlights potential of lead asset
• Seeking Alpha Catalyst Watch
• ArTara Therapeutics EPS misses by $0.47
• Protara announces path forward for further development of lead asset